Venaxis, Inc. to Webcast Live at RetailInvestorConferences.com on February 7, 2013 Company Invites Main Street and Wall Street Investors to Attend Interactive Real-time Virtual Conference PR Newswire CASTLE ROCK, Colo., Feb. 4, 2013 CASTLE ROCK, Colo., Feb. 4, 2013 /PRNewswire/ --Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its blood-based appendicitis test, APPY1, today announced that Steve Lundy, President and Chief Executive Officer, will present at RetailInvestorConferences.com. DATE: February 7, 2013 TIME: 10:00 AM EST LINK: www.retailinvestorconferences.com > Click red "register / watch event now" button This will be a live, interactive online event where investors are invited to ask the company questions in real-time, both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days. It is recommended that investors pre-register to save time and receive event updates. About Venaxis, Inc. Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test, APPY1. The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. APPY1 is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. For more information, visit www.venaxis.com. About RetailInvestorConferences.com: Since 2010, RetailInvestorConferences.com has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network. Forward-Looking Statements This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") (formerly AspenBio Pharma, Inc.) as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for APPY1 required for FDA submission, obtain FDA clearance or approval, complete and maintain CE Marking, cost effectively manufacture and generate revenues from APPY1, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the period ended September 30, 2012, filed on November 7, 2012. SOURCE Venaxis, Inc. Website: http://www.venaxis.com Contact: Venaxis, Inc. - For Investors & Media - Joshua Drumm, PhD, firstname.lastname@example.org, or Jason Rando, email@example.com, both of Tiberend Strategic Advisors, Inc., +1-212-827-0020; RetailInvestorConferences.com - Bradley H. Smith, firstname.lastname@example.org, +1-201-942-7157
Venaxis, Inc. to Webcast Live at RetailInvestorConferences.com on February 7, 2013
Press spacebar to pause and continue. Press esc to stop.